16.09.2024 14:20:44
|
Sanofi To Offer BEYFORTUS Doses To Protect Babies During RSV Season - Quick Facts
(RTTNews) - Sanofi (SNYNF, SNY) said it is shipping BEYFORTUS 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for Disease Control and Prevention for its Vaccines for Children program.
BEYFORTUS is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
For More Such Health News, visit rttnews.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sanofi S.A.mehr Nachrichten
Analysen zu Sanofi S.A.mehr Analysen
24.01.25 | Sanofi Neutral | JP Morgan Chase & Co. | |
23.01.25 | Sanofi Buy | UBS AG | |
16.01.25 | Sanofi Neutral | JP Morgan Chase & Co. | |
07.01.25 | Sanofi Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
07.01.25 | Sanofi Outperform | Bernstein Research |
Aktien in diesem Artikel
Sanofi S.A. (spons. ADRs) | 50,50 | 0,00% | |
Sanofi S.A. | 103,68 | 3,16% |